Extract from Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2022
Diagnostic criteria for dyslipidemia
LDL cholesterol
≥140mg/dL
LDL-hypercholesterolemia
120 – 139mg/dL
Borderline LDL-hypercholesterolemia**
HDL cholesterol
<40mg/dL
HDL-hypocholesterolemia
Triglyceride
≥150mg/dL (fasting blood collection*)
Hypertriglyceridemia
≥175mg/dL (Blood collection at any time*)
Non-HDL cholesterol
≥170mg/dL
Non-HDL-hypercholesterolemia
150 – 169mg/dL
Borderline non-HDL-hypercholesterolemia**
* Basically, “Fasting” means abstinence from food for at least 10 hours. However, zero-calorie water or tea intake is permitted. If the patient is not confirmed to be in a fasting state, "any time" is defined.
** For patients classified as borderline LDL-hyper C, borderline non-HDL-C in the screening, examine their high-risk clinical conditions and consider the need for treatment.
Use the Friedewald method (TC-HDL-C-TG/5) to obtain LDL-C levels. (However this is limited to fasting blood collection). Or use the direct methods.
Use non-HDL-C (=TC-HDL-C) or LDL-C direct methods for patients with 400mg/dL of TG or higher, or blood collection at any time. When assessing the risk, however, remember that the difference from LDL-C may be smaller than +30mg/dL in patients without hypertriglyceridemia at the screening when using non- HDL-C.
Reference value of TG is different between fasting blood collection and blood collection at any time.
It is not subject to drug intervention in case of using only HDL-C.
Flow chart for setting LDL cholesterol target values from the perspective of coronary artery disease prevention using Suita score
Calculate based on score by Hisayama Study (Figure 3-2)
**50% or more of stenosis in internal, or external cranial arteries or arch aortic atheroma (maximal thickening ≥4 mm)
Note) Refer to Chapter 4 "Familial cholesterolemia", Chapter 5 "Primary dyslipidemia" instead of using this chart for patients with diagnosis of familial hypercholesterolemia and familial type Ⅲ hyperlipidemia, respectively.
Lipid target values by risk segment
Therapeutic principle
Control segment
Lipid target values (mg/dL)
LDL-C
Non HDL-C
TG
HDL-C
Primary prevention
After improving lifestyle, consider drug therapy.
Low risk
<160
<190
<150 (when fasting) ***
<175(at any time)
≥40
Medium risk
<140
<170
High risk
<120
<100*
<150
<130*
Secondary prevention
Consider drug therapy together with improving lifestyle.
Have history of coronary artery diseases or atherothrombotic brain infarction(including other brain infarction that clearly has atherom ****)
<100 <70*
<130 <100**
* In diabetes, consider in the presence of PAD, microangiopathy (retinopathy, nephropathy, neuropathy) complications, or in the presence of smoking. (See Chapter 3, 5.2)
** To be considered when any of the four disease states "Acute coronary syndrome", "Familial cholesterolemia", " diabetes", or "coronary artery diseases or atherothrombotic brain infarction (including other brain infarction that clearly has atherom" are combined.
In principle, use non-drug therapy to achieve the target values in the primary prevention. However, for any control segment with LDL-C levels ≥ 180mg/dL, consider drug therapy and also the possibility of familial hypercholesterolemia (refer to Chapter 4).
First, achieve the target value of LDL-C and then aim to achieve the target value of non-HDL-C. Even if LDL-C target values are achieved, high non-HDL-C is often associated with hypertriglyceridemia, which is important to manage. Low HDL-C should basically be addressed with lifestyle improvement.
These values represent a goal to strive for. Target values can also be LDL-C reduction rate of 20–30% in the primary prevention (low/medium risk).
*** “Fasting” means abstinence from food for at least 10 hours. However, zero-calorie water or tea intake is permitted. The other conditions are defined as "any time".
****50% or more of stenosis in internal or external cranial arteries or arch aortic atheroma (maximal hickening ≥4 mm)
Refer to Chapter 7 for elderly patients
Sources: Edited by Japan Atherosclerosis Society: Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2022, Japan Atherosclerosis Society, 2022 (revised)
Notifications of URL changes/lab information added
You can now view test items from all labs.
Please choose a lab from the list below.
You can switch between labs as any time using the upper right lab icon.
The domain name of the TEST DIRECTORYpage has changed.
Please update bookmarks and saved links with the new address.
Notifications of URL changes/lab information added
You can now view test items from all labs.
Please choose a lab from the list below.
You can switch between labs as any time using the upper right lab icon.
The domain name of the TEST DIRECTORYpage has changed.
Please update bookmarks and saved links with the new address.